Why Global Pull Incentives Matter For AMR Drugs

Tokyo Meeting Hears Views

The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.

Pull incentive model in a global scale is necessary for the sustainability for AMR drugs, Shionogi and GARDP say.
global pull incentive model necessary for sustainability of AMR drugs, Shionogi and GARDP say • Source: Shutterstock

The sustainable supply of drugs for antimicrobial resistance (AMR) is needed on a global scale. However, this will require both pull incentive models for reimbursement and high technology for producing molecules with complex structures, while also ensuring compliance with Good Manufacturing Practice (GMP) standards. 

More from Anti-infective

More from Therapy Areas

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By 

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.

Axsome Scores In ADHD, But Differentiation In Generic-Heavy Market Unclear

 

The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.

GSK’s Blujepa Brings Innovation To The Antibiotic Space

 

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.